Details for New Drug Application (NDA): 213434
✉ Email this page to a colleague
The generic ingredient in PACLITAXEL is paclitaxel. There are sixty-nine drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the paclitaxel profile page.
Summary for 213434
| Tradename: | PACLITAXEL |
| Applicant: | Msn |
| Ingredient: | paclitaxel |
| Patents: | 0 |
Pharmacology for NDA: 213434
| Physiological Effect | Microtubule Inhibition |
Medical Subject Heading (MeSH) Categories for 213434
Suppliers and Packaging for NDA: 213434
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| PACLITAXEL | paclitaxel | INJECTABLE;INJECTION | 213434 | ANDA | Northstar Rx LLC | 16714-137 | 16714-137-01 | 1 VIAL, MULTI-DOSE in 1 CARTON (16714-137-01) / 50 mL in 1 VIAL, MULTI-DOSE |
| PACLITAXEL | paclitaxel | INJECTABLE;INJECTION | 213434 | ANDA | BluePoint Laboratories | 68001-516 | 68001-516-27 | 1 VIAL, MULTI-DOSE in 1 CARTON (68001-516-27) / 50 mL in 1 VIAL, MULTI-DOSE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 6MG/ML | ||||
| Approval Date: | Aug 24, 2020 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
